Shots:

• The approval follows two P-III studies (COAST V & COAST W) assessing Taltz (q4w) vs PBO in 657 patients with active AS who are bDMARD-naïve & intolerant to TNF inhibitors respectively
• The P-III studies result:  improvement in 1EPs i.e. achievement of ASAS40 @16wks. (48% & 25% vs 18% & 13%); improvement in 2EPs (64% & 48% vs 40% & 30%); safety profile is consistent with psoriasis patients
• Taltz is a mAb targeting IL-17A thus inhibiting its interaction with IL-17 receptor and hinders the release of pro-inflammatory cytokines and chemokines and has received Health Canada’s approval for PsO & PsA in 2016 and 2018 respectively

Click here ­to­ read full press release/ article 

Ref: GlobeNewswire | Image: Eli Lilly